secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001558370-24-015779
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M
----------------------------------------------------------------------

- Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.
- Cash of $0.6M as of Sept 30, 2024 (Dec 31, 2023: $1.1M); operating cash burn $7.7M YTD 2024.
- Initiated BP1001-A obesity program in October, first non-oncology application of DNAbilize technology targeting Grb2 insulin resistance.
- Completed enrollment for third dose cohort of BP1002 Phase 1/1b trial in venetoclax-resistant AML patients ahead of schedule.
- Closed $4.0M private placement in October: 4.6M shares and warrants at $0.87 per unit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/0001558370-24-015779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/bpth-20241115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer